Stephanie Arnold
Family · Terre Haute, INNPI 1508159096
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,004 of the $51,544 with a category attached, or 89.3%. Sanofi-aventis U.S. LLC accounts for 64.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $24,888 and has fallen 90.3% since, to $2,415 in 2025. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $237.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$33K
- Novo Nordisk$16K
- Insulet Corporation$502
- AstraZeneca$324
- Sequel Med Tech, LLC$215
- Tandem Diabetes Care, Inc.$204
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$46,00489%
- Travel & lodging$1,0562%
- Food & beverage$4,3839%
- Education$430%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 86 | $33,410 |
| Novo Nordisk | 55 | $15,698 |
| Insulet Corporation | 11 | $502 |
| AstraZeneca | 10 | $324 |
| Sequel Med Tech, LLC | 2 | $215 |
| Tandem Diabetes Care, Inc. | 3 | $204 |
| Mannkind Corporation | 7 | $186 |
| Bayer | 5 | $140 |
| BETA Bionics, Inc. | 1 | $125 |
| Medtronic | 3 | $122 |
| Lilly USA, LLC | 6 | $107 |
| AbbVie | 5 | $88 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Cequr Corporation | 2 | $46 |
| Averitas Pharma Inc. | 2 | $45 |
| Antares Pharma, Inc. | 3 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Abbott | 2 | $31 |
| Boehringer Ingelheim | 1 | $29 |
| Corcept Therapeutics | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$19,892
- TOUJEO$12,669
- RYBELSUS$7,618
- Ozempic$4,412
- iLet Bionic Pancreas$374
- Omnipod$369
- TWIIST$204
- iLet Insulin Infusion Kit Inset$125
- iLet Insulin Infusion Kit Contact Detach$125
- t:slim X2 Insulin Pump with Control-IQ$112
- FARXIGA$100
How this compares
$51,544 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 505 | $575,390 |
| OzempicSemaglutide | 311 | $386,734 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 128 | $145,061 |
| FarxigaDapagliflozin Propanediol | 145 | $99,596 |
| Tresiba Flextouch U-100Insulin Degludec | 150 | $90,475 |
| TrulicityDulaglutide | 63 | $83,027 |
| JardianceEmpagliflozin | 97 | $77,287 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $76,866 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $70,140 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $66,504 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 57 | $49,732 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $47,601 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $44,450 |
| LyumjevInsulin Lispro-Aabc | 24 | $32,683 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 23 | $30,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $107 | $736,801784 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $15,698 | $446,743385 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $29 | $105,969135 claims |
| AstraZenecaFarxiga | $324 | $99,596145 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $33,410 | $49,73257 claims |
| AbbVieSynthroid | $88 | $12,759150 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $11,995584 claims |
| Antares Pharma, Inc.Xyosted | $41 | $8,82713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.